A Phase 2, open label study of rucaparib in patients with advanced pancreatic cancer and a known deleterious germline or somatic BRCA or PALB2 mutation. NCT03140670
Bailey P et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531(7592):47-52. Abstract
Goggins M et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56(23):5360-4. Abstract
Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381(4):317-27. Abstract
Golan T et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111(6):1132-8. Abstract
Hofstatter EW et al. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 2011;10(2):225-33. Abstract
Kaufman HL et al. Precision immunology: The promise of immunotherapy for the treatment of cancer. J Clin Oncol 2015;33(12):1315-7. Abstract
Park W et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res 2020;26(13):3239-47. Abstract
PARPVAX: Parpvax: A phase 1b/2, open label study of niraparib plus either ipilimumab or nivolumab in patients with advanced pancreatic cancer whose disease has not progressed on platinum-based therapy. NCT03404960
Pishvaian MJ et al. Molecular profiling of patients with pancreatic cancer: Initial results from the Know Your Tumor Initiative. Clin Cancer Res 2018;24(20):5018-27. Abstract
Premnath N et al. BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies. Chin Clin Oncol 2020;cco-2019-ddp-05. Abstract
Salo-Mullen EE et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 2015;121(24):4382-8. Abstract
Shroff RT et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol;2018:10.1200/PO.17.00316. Abstract
Singhi AD et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 2019;156(8):2242-53.e4. Abstract